Top news from VIVA: Drug-coated devices, treatments for PAD and more
Healio and Cardiology Today have aggregated the most-read news from the virtual VIVA 20.
Readers were most interested in the use of drug-coated devices and intravascular lithotripsy in peripheral artery disease, deep venous arterialization for severe CLI and more.
Pooled analysis shows no 4-year mortality risk with low-dose PCB
In a pooled analysis of two randomized controlled trials of a low-dose paclitaxel-coated balloon to treat PAD, there was no mortality difference between the paclitaxel-coated balloon and an uncoated balloon at 4 years. Read more
DETOUR I: Percutaneous bypass system safe, effective at 24 months
A fully percutaneous bypass system using the femoral vein as a conduit was associated with high rates of patency and low rates of complications at 24 months in patients with severe PAD. Read more
Drug-coated devices associated with less unplanned limb revascularization: VOYAGER PAD
Among patients with PAD who had an endovascular procedure, treatment with a drug-coated device was linked to lower risk for unplanned limb revascularization, according to new data from the VOYAGER PAD trial. Read more
DCB remains effective in real-world PAD population at 5 years
In a real-world population of patients with PAD treated with a drug-coated balloon, nearly 70% remained free from clinically driven target lesion revascularization at 5 years, according to data presented at VIVA 20. Read more
Intravascular lithotripsy superior to PTA in patients with calcified PAD
In patients with calcified peripheral artery lesions treated with a drug-coated balloon, those who were pretreated with intravascular lithotripsy had better procedural outcomes than those pretreated with angioplasty, a speaker said at VIVA 20. Read more
Deep venous arterialization may benefit patients with severe CLI
In the single-arm PROMISE I study of deep venous arterialization in patients with severe critical limb ischemia, seven of 10 survived and were free from amputation at 1 year, according to data presented at the virtual VIVA 20. Read more
Bioabsorbable scaffold benefits high-risk patients with infrapopliteal disease
In a pooled analysis of three single-center studies, a bioresorbable scaffold was associated with high rates of patency and low rates of adverse events at 2 years in high-risk patients with infrapopliteal artery lesions. Read more